Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: ...
One day after a short seller claimed that St. Jude Medical Inc's heart implants are vulnerable to deadly cyber attacks, investors appear most concerned about whether the accusation will derail St. Jude's $24 billion planned deal for Abbott Labs to buy it. St. Jude's stock at one point fell around 3 percent on Friday, though it ended the day slightly up, following a drop of around 5 percent on Thursday after Muddy Waters Capital leveled the accusation against St. Jude. St. Jude in April agreed to sell itself to Abbott, and the deal was widely considered a slam dunk before the cyber security concerns were raised.
- CNBC•2 days ago
Alere fell 3 percent after it sued Abbott to compel it to get all antitrust approvals required to complete its $5.8 billion merger.
Abbott Laboratories (ABT)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||42.96 x 100|
|Ask||43.08 x 100|
|Day's Range||42.09 - 43.28|
|52wk Range||36.00 - 46.63|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.37|
|Avg Vol (3m)||10,372,698|
|Dividend & Yield||1.04 (2.42%)|